Mometason Apofri (Mometasone Furoate)

Mometasone Furoate, the active ingredient in Mometason Apofri, is a corticosteroid presented as a nasal formulation for intranasal use. It reduces nasal inflammation and is used to treat allergic rhinitis in adults and children.

GNH USA supplies Mometason Apofri as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mometason Apofri, a nasal corticosteroid, is employed to manage inflammatory conditions of the nasal passages.

Allergic rhinitis: alleviates nasal congestion, itching and sneezing caused by seasonal or perennial allergens. Nasal polyposis: reduces size of nasal polyps and improves airflow. Seasonal allergic rhinitis: controls symptoms triggered by pollen exposure. Perennial allergic rhinitis: provides year‑round relief from indoor allergen‑induced nasal symptoms.

Mometason Apofri may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nasal irritation or burning sensation. - Headache. - Epistaxis (nosebleeds). - Throat irritation. - Unpleasant taste. - Cough.

Serious or Rare Side Effects: - Nasal septal perforation. - Secondary fungal or bacterial infections of the nasal mucosa. - Elevated intra‑ocular pressure or glaucoma. - Adrenal suppression with prolonged high‑dose use. - Severe allergic reaction (anaphylaxis). - Vision changes.

Before using Mometason Apofri, consider the following safety measures.

Pregnancy: consult a healthcare professional before use. Breastfeeding: discuss potential risks with a physician. Age restrictions: not recommended for children under two years of age. Existing infections: monitor for fungal or bacterial nasal infections. Surgery: inform the surgeon of nasal steroid use prior to procedures. Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mometason Apofri can interact with other medicines; awareness of these interactions helps maintain safety.

Major Interactions (Avoid): - Systemic corticosteroids: may increase systemic glucocorticoid exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise local drug concentrations.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., fluconazole): may modestly increase exposure. - Antihistamines: additive sedative effect is unlikely but monitor for increased drowsiness. - Live vaccines: nasal steroids may reduce vaccine efficacy. - Nasal decongestants: concurrent use may increase risk of nasal irritation.